National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation, Moscow, Russia.
Bull Exp Biol Med. 2020 Jul;169(3):361-364. doi: 10.1007/s10517-020-04887-6. Epub 2020 Aug 3.
The use of lytic mycobacteriophages to treat tuberculosis under conditions of acquired resistance to anti-tuberculosis drugs is one of the most practical ways to improve the effectiveness of therapy and reduce the spread of this disease. We studied the efficacy of antimycobacterial action of mycobacteriophage D29 encapsulated into 400-nm liposomes in cell models of tuberculosis infection in vitro. The antimycobacterial action of lytic mycobacteriophage D29 used in free or liposome-encapsulated forms was demonstrated on cell models of intracellularly infected RAW264.7 macrophages and tuberculous granuloma formed by human blood mononuclear cells. The experiments demonstrated pronounced advantage of liposomal form of mycobacteriophage according to the criteria of their penetration into macrophages and lysis of Mycobacterium tuberculosis in culture.
利用裂解分枝杆菌噬菌体在获得抗结核药物耐药的情况下治疗结核病，是提高治疗效果和减少该疾病传播的最实用方法之一。我们研究了将分枝杆菌噬菌体 D29 包裹在 400nm 脂质体中，在体外结核感染细胞模型中的抗分枝杆菌作用。在细胞内感染 RAW264.7 巨噬细胞和人血单核细胞形成的结核肉芽肿的细胞模型中，研究了游离或脂质体包裹的裂解分枝杆菌噬菌体的抗分枝杆菌作用。实验根据噬菌体进入巨噬细胞和裂解培养的结核分枝杆菌的能力，证明了分枝杆菌噬菌体脂质体形式具有明显的优势。
